Table 1. Baseline demographic and clinical characteristics.
| Intervention group (n = 106) | Control group (n = 102) | p value | |
| Male (%) | 88 (83%) | 87 (85.3%) | 0.65 |
| Age, years | 60.1 ± 12.4 | 61.5 ± 12.2 | 0.41 |
| ≥ 65 years | 36 (34%) | 40 (39.2%) | 0.43 |
| BMI (kg/m2) | 21.3 ± 4.3 | 22.0 ± 6.8 | 0.353 |
| Literacy rate (%) | 97 (91.5%) | 88 (86.3%) | 0.23 |
| Smoking (%) | 43 (40.6%) | 51 (50%) | 0.22 |
| Creatinine (mg/dL) | 1.59 ± 2.12 | 1.47 ± 1.69 | 0.662 |
| eGFR | 57.75 ± 13.13 | 66.75 ± 13.21 | 0.330 |
| Hypertension | 78 (73.6%) | 74 (72.5%) | 0.87 |
| Hyperlipidemia | 81 (76.4%) | 75 (73.5%) | 0.73 |
| Diabetes | 35 (33%) | 36 (35.3%) | 0.729 |
| CVA | 6 (5.7%) | 5 (4.9%) | 0.81 |
| CKD | 21 (19.8%) | 20 (19.6%) | 0.97 |
| Drug therapy | |||
| Aspirin | 96 (90.6%) | 90 (88.2%) | 0.59 |
| Clopidogrel | 103 (97.2%) | 102 (100%) | 0.26 |
| Dual antiplatelet | 93 (87.7%) | 91 (89.2%) | 0.74 |
| β-blockers | 87 (82.1%) | 84 (82.4%) | 0.96 |
| ACEIs | 39 (36.8%) | 39 (38.2%) | 0.83 |
| ARBs | 51 (48.1%) | 47 (46.1%) | 0.77 |
| ACEIs or ARBs | 93 (87.7%) | 89 (87.3%) | 0.92 |
| Statins | 92 (86.8%) | 84 (82.4%) | 0.38 |
ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; MRF, modifiable risk factor.